2-[2-(4-Carbamimidoyl-benzenesulfonylamino)-acetylamino]-3-(4-carbamimidoyl-phenyl)-propionic acid ethyl ester

ID: ALA135815

PubChem CID: 10435038

Max Phase: Preclinical

Molecular Formula: C21H26N6O5S

Molecular Weight: 474.54

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  CCOC(=O)C(Cc1ccc(C(=N)N)cc1)NC(=O)CNS(=O)(=O)c1ccc(C(=N)N)cc1

Standard InChI:  InChI=1S/C21H26N6O5S/c1-2-32-21(29)17(11-13-3-5-14(6-4-13)19(22)23)27-18(28)12-26-33(30,31)16-9-7-15(8-10-16)20(24)25/h3-10,17,26H,2,11-12H2,1H3,(H3,22,23)(H3,24,25)(H,27,28)

Standard InChI Key:  RHXBSZXVGSHOPS-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 33 34  0  0  0  0  0  0  0  0999 V2000
    5.8917   -3.2292    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    5.3167   -3.0792    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.5667   -2.6167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8250   -2.4250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2042   -3.8417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4125   -2.0375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1500   -2.7667    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.4750   -3.3875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3125   -3.3542    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8917   -3.5125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0500   -3.8167    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.3167   -2.8042    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.6250   -3.6875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4042   -2.5792    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5542   -1.8917    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.6292   -3.4167    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.1417   -3.0500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8292   -1.8792    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.8875   -3.7750    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.6292   -3.9625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8917   -2.9625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4667   -3.1125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2042   -4.1125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5667   -3.1625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8292   -2.1542    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3667   -4.4167    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.4917   -2.9292    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.5667   -2.8917    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8375   -1.6042    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.1417   -3.3167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4125   -2.3042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4167   -1.7625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8375   -1.3292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  0
  3  7  1  0
  4 14  1  0
  5 13  1  0
  6  3  1  0
  7  9  1  0
  8  1  1  0
  9 10  1  0
 10  2  1  0
 11  1  2  0
 12  1  2  0
 13 22  1  0
 14 25  2  0
 15  4  2  0
 16  5  2  0
 17  3  1  0
 18  6  2  0
 19  9  2  0
 20  8  2  0
 21  8  1  0
 22 21  2  0
 23 20  1  0
 24 30  2  0
 25 31  1  0
 26  5  1  0
 27  4  1  0
 28 17  1  0
 29  6  1  0
 30 28  1  0
 31 28  2  0
 32 29  1  0
 33 32  1  0
 13 23  2  0
 14 24  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA135815

   2-[2-(4-Carbamimidoyl-benzenesulfonylamino)-acetylamino]-3-(4-carbamimidoyl-phenyl)-propionic acid ethyl ester

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 474.54

Molecular Weight (Monoisotopic): 474.1685

AlogP: -0.18

#Rotatable Bonds: 11

Polar Surface Area: 201.31

Molecular Species: BASE

HBA: 7

HBD: 6

#RO5 Violations: 1

HBA (Lipinski): 11

HBD (Lipinski): 8

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 9.50

CX Basic pKa: 11.39

CX LogP: -0.85

CX LogD: -4.72

Aromatic Rings: 2

Heavy Atoms: 33

QED Weighted: 0.15

Np Likeness Score: -0.76

References

1. Gabriel B, Stubbs MT, Bergner A, Hauptmann J, Bode W, Stürzebecher J, Moroder L..  (1998)  Design of benzamidine-type inhibitors of factor Xa.,  41  (22): [PMID:9784099] [10.1021/jm980227t]

2. Maduskuie, T P TP, McNamara, K J KJ, Ru, Y Y, Knabb, R M RM and Stouten, P F PF.  1998-01-01  Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors.  [PMID:9438022]

3. Quan, M L ML and 11 more authors.  1999-07-29  Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1.  [PMID:10425086]

4. Quan, M L ML and 8 more authors.  1999-07-29  Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2.  [PMID:10425087]

5. Ewing, W R WR and 23 more authors.  1999-09-09  Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.  [PMID:10479288]

6. Choi-Sledeski, Y M YM and 22 more authors.  1999-09-09  Sulfonamidopyrrolidinone factor Xa inhibitors: potency and selectivity enhancements via P-1 and P-4 optimization.  [PMID:10479289]

7. Han, Q Q and 13 more authors.  2000-11-16  Design, synthesis, and biological evaluation of potent and selective amidino bicyclic factor Xa inhibitors.  [PMID:11087565]

8. Pinto, D J DJ and 17 more authors.  2001-02-15  Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa.  [PMID:11170646]

9. Su, T T and 14 more authors.  2001-09-03  Design and synthesis of glycolic and mandelic acid derivatives as factor Xa inhibitors.  [PMID:11527714]

10. Quan, Mimi L ML and 11 more authors.  2003-02-10  Nonbenzamidine tetrazole derivatives as factor Xa inhibitors.  [PMID:12565931]

11. Quan, Mimi L ML and 10 more authors.  2003-03-24  Nonbenzamidine isoxazoline derivatives as factor Xa inhibitors.  [PMID:12643903]

12. Ueno, Hiroshi H and 9 more authors.  2005-05-19  Synthesis and structure-activity relationships of novel selective factor Xa inhibitors with a tetrahydroisoquinoline ring.  [PMID:15887966]

13. Pinto, Donald J P DJ and 21 more authors.  2006-08-01  1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.  [PMID:16730984]

14. Steinmetzer, Torsten T and 11 more authors.  2006-07-13  Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase.  [PMID:16821772]

15. Lin, Jian J and 19 more authors.  2006-12-28  Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.  [PMID:17181160]

16. Ye, Bin B and 30 more authors.  2007-06-28  Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors.  [PMID:17536795]

17. Wong, P C PC and 7 more authors.  2008-05  Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies.  [PMID:18315548]

18. Imaeda, Yasuhiro Y and 9 more authors.  2008-06-26  Discovery of imidazo[1,5-c]imidazol-3-ones: weakly basic, orally active factor Xa inhibitors.  [PMID:18507371]

19. Qiao, Jennifer X JX and 9 more authors.  2009-01-15  Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties.  [PMID:19046881]

20. de Candia, Modesto M, Liantonio, Francesco F, Carotti, Andrea A, De Cristofaro, Raimondo R and Altomare, Cosimo C.  2009-02-26  Fluorinated benzyloxyphenyl piperidine-4-carboxamides with dual function against thrombosis: inhibitors of factor Xa and platelet aggregation.  [PMID:19193009]

21. Kotian, Pravin L PL and 9 more authors.  2009-06-01  Design, parallel synthesis, and crystal structures of biphenyl antithrombotics as selective inhibitors of tissue factor FVIIa complex. Part 1: Exploration of S2 pocket pharmacophores.  [PMID:19409795]

22. Wang, Shouming S and 20 more authors.  2010-02-25  Structure based drug design: development of potent and selective factor IXa (FIXa) inhibitors.  [PMID:20121197]

23. Wang, Shouming S and 14 more authors.  2010-02-25  Studies of benzothiophene template as potent factor IXa (FIXa) inhibitors in thrombosis.  [PMID:20121198]

24. Correia-da-Silva, Marta M and 6 more authors.  2011-08-11  Polysulfated xanthones: multipathway development of a new generation of dual anticoagulant/antiplatelet agents.  [PMID:21732671]

25. Pandya, Vrajesh V and 17 more authors.  2012-12  Synthesis and structure-activity relationship of potent, selective and orally active anthranilamide-based factor Xa inhibitors: application of weakly basic sulfoximine group as novel S4 binding element.  [PMID:23124211]

26. Meneyrol, Jerome J and 20 more authors.  2013-12-12  5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor.  [PMID:24175584]

27. Zhang, Xiaojun X and 17 more authors.  2016-08-11  Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex.  [PMID:27455395]

28. Ladziata, Vladimir Uladzimir VU and 13 more authors.  2016-10-15  Synthesis and P1' SAR exploration of potent macrocyclic tissue factor-factor VIIa inhibitors.  [PMID:27612545]

29. Wang, Yong Y and 11 more authors.  2016-11-01  Design, synthesis, and structure-activity relationship of novel and effective apixaban derivatives as FXa inhibitors containing 1,2,4-triazole/pyrrole derivatives as P2 binding element.  [PMID:27663548]

30. Sun, Xiaoqing X and 10 more authors.  2017-05-15  Design, synthesis, and biological activity of novel tetrahydropyrazolopyridone derivatives as FXa inhibitors with potent anticoagulant activity.  [PMID:28389110]

31. and Fischer, Peter M PM.  2018-05-10  Design of Small-Molecule Active-Site Inhibitors of the S1A Family Proteases as Procoagulant and Anticoagulant Drugs.  [PMID:29072911]

32. Qiu, Xiaomiao X and 5 more authors.  2019-01  Effect of a new inhibitor of factor Xa zifaxaban, on thrombosis in the inferior vena cava in rabbits.  [PMID:30298304]

33. Xing, Junhao J, Yang, Lingyun L, Zhou, Jinpei J and Zhang, Huibin H.  2018-12-15  Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.  [PMID:30446438]

34. Swedberg, Joakim E JE, Ghani, Hafiza Abdul HA, Harris, Jonathan M JM, de Veer, Simon J SJ and Craik, David J DJ.  2018-12-13  Potent, Selective, and Cell-Penetrating Inhibitors of Kallikrein-Related Peptidase 4 Based on the Cyclic Peptide MCoTI-II.  [PMID:30613336]

35. Wang, Dong D and 8 more authors.  2019-02-28  Suppression of Tumor Growth and Metastases by Targeted Intervention in Urokinase Activity with Cyclic Peptides.  [PMID:30707839]

36. Walker, Ann L and 19 more authors.  2019-10-15  Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors.  [PMID:31521475]

37. Chen, Peng and 11 more authors.  2019-12-01  Discovery of novel, potent, isosteviol-based antithrombotic agents.  [PMID:31563807]

Source

Source(1):

• Scientific Literature